ID 902 -
	
		
			Lactobacillus plantarum 299v
		
		
		
	 
PL: Lactobacillus plantarum 299v
EN: Lactobacillus plantarum 299v
Pdf: Lactobacillus plantarum 299v
 
        
        
                
1. Charakterystyka żywności / składnika
                
                
                    The food constituent that is the subject of the health claims is Lactobacillus plantarum 299v. The  identification and characterisation of the strain Lactobacillus plantarum 299v by both phenotypic and  genotypic methods is included in some of the studies provided as reference material (Johansson et al.,  1993; 1995; 1998).  
In the references provided, the deposit of the strain at the DSMZ (Deutsche Sammlung von  Mikroorganismen und Zellkulturen) with a deposit number DSM 9843 is cited (Johansson et al.,  1998; Klarin et al., 2005).  
The Panel considers that the strain, Lactobacillus plantarum 299v, which is the subject of the health  claims, is sufficiently characterised.  
                 
                 
	        
        
        
        
        
                
2.1. Redukcja wzdęć i gazów (ID 902)
                
                
                    The claimed effect is “digestive system”. The Panel assumes that the target population is the general  population.   
In the context of the proposed wording, the Panel assumes that the claimed effect refers to reducing  flatulence and bloating. Excessive flatulence and bloating may cause abdominal pain and discomfort.  
The Panel considers that reduction of flatulence and bloating is a beneficial physiological effect.  
                 
                 
	        
        
        
        
        
                
3.1. Redukcja wzdęć i gazów (ID 902)
                
                
                    A number of references provided for the scientific substantiation of the claim were unrelated to the  food constituent which is the subject of the health claim, or were human, animal and in vitro studies  on Lactobacillus plantarum 299v and effects other than reduction of flatulence and bloating. These  references included studies related to the treatment of recurrent Clostridium difficile-associated  diarrhoea, to effects on secretory response of intestinal epithelial cells to enteropathogenic  Escherichia coli infection, to effects on bacterial translocation, and to plasma total antioxidant  capacity, selenium status and faecal microbiota. The Panel considers that no conclusions can be  drawn from these references for the scientific substantiation of the claimed effect.  
Among the references cited, only three papers (Johansson et al., 1998; Niedzielin et al., 2001; Nobaek  et al., 2000) addressed outcomes related to the claimed effect.   
In a controlled and randomised, double-blind study (Johansson et al., 1998) 26 healthy adult  volunteers consumed, for 21 days, 400 mL of a rose-hip drink containing oats (0.7 g/100 mL)  fermented with Lactobacillus plantarum DSM 9843 (5x107 CFU/mL), and 22 volunteers in a second  group the same amount of a pure rose-hip drink without oat (control, without the strain and without  oat). The authors stated that the test product and placebo were comparable in texture and taste. Only  at the end of the intervention were volunteers asked to note their overall bowel function observed  during the intervention period. The results were reported by using analogue scales. The questions in  the scales were: stool frequency, volume and consistency, difficulty with defecation and degree of  flatulence. The Panel notes that this study was not appropriately controlled for other substances  besides Lactobacillus plantarum DSM 9843, that no information was given on the background diets  of subjects enrolled in the study, that it was not established that test and control groups were  comparable at baseline with regard to the outcomes measured, that no information was given about  the validation of the scale used, and that subjects were asked only at the end of the study periods to  fill in the questionnaire evaluating the endpoints before and after intervention, for which reason recall  bias cannot be excluded. The Panel considers that no conclusions can be drawn from this study for the  scientific substantiation of the claimed effect.  
In another study (Nobaek et al., 2000), 60 patients with irritable bowel syndrome (IBS) and a normal  colonoscopy or barium enema were randomised into two groups, one receiving 400 mL per day of a  rose-hip drink containing 5x107 CFU/mL of Lactobacillus plantarum (DSM 9843) and 0.9 g/100 mL  oat flour, and the other receiving a plain rose-hip drink without oat (control, without the strain and  without oat), for four weeks. The authors stated that the test product and placebo were comparable in  colour, texture, and taste. The patients recorded daily their gastrointestinal function in a questionnaire  which included bloating and flatulence (the latter was recorded once a week), starting two weeks  before the study and continuing throughout the study period. The Panel notes that this study was not 
9v related health claims  
7 EFSA Journal 2010;9(4):2037  
appropriately controlled for other substances besides Lactobacillus plantarum DSM 9843, that no  information was given on the background diets of subjects enrolled in the study and that no  information was given about the validation of the scale used. The Panel considers that no conclusions  can be drawn from this study for the scientific substantiation of the claimed effect.   
In the study by (Niedzielin et al., 2001), 40 patients (mean age 45 years, range 27-63 years) with  irritable bowel syndrome (IBS) were randomised to receive 200 mL twice a day of a fruit drink  containing 5 % oatmeal soup fermented with Lactobacillus plantarum 299v (5x107 CFU/mL; 20  patients) or of a placebo (fruit drink containing 5 % oatmeal soup without the strain) with identical  appearance, smell and taste (20 patients) over a period of four weeks. Clinical examination was  performed at baseline and at the end of the study. Additionally, patients assessed their symptoms on a  weekly basis, applying a specially designed scoring system. The system included the three major  symptoms of IBS: abdominal pain, stool frequency and consistency, and flatulence. The primary  outcome measure was pain relief. The overall score was considered as the secondary outcome  measure. The Panel notes that no information was given regarding the validation of the specially  designed scoring system used, that no indication was provided that the study had been stratified a  priori for the type of IBS with respect to symptoms, and that the statistical evaluation did not use a  test allowing analysis of multiple repeated measures. The Panel considers that no conclusions can be  drawn from this study for the scientific substantiation of the claimed effect.   
In weighing the evidence, the Panel took into account that no conclusions can be drawn for the  scientific substantiation of the claimed effect from the three studies provided that addressed outcomes  related to the claimed effect.  
The Panel concludes that a cause and effect relationship has not been established between the  consumption of Lactobacillus plantarum 299v and reduction of flatulence and bloating.  
                 
                 
	        
        
Warunki i możliwe ograniczenia stosowania oświadczenia
at least 20x109 cfu/ day